scout
|Videos|August 18, 2017

Dr. Black on Selecting Immunotherapy Agents in Bladder Cancer

Peter Black, MD, senior research scientist, Vancouver Prostate Centre, associate professor, Department of Urologic Sciences, University of British Columbia, discusses selecting immunotherapy agents in bladder cancer.

Peter Black, MD, senior research scientist, Vancouver Prostate Centre, associate professor, Department of Urologic Sciences, University of British Columbia, discusses selecting immunotherapy agents in bladder cancer.

Right now, there is not a clear-cut option for immunotherapy in the treatment of bladder cancer. It is currently up to treating physicians’ preference.

Every other day there are new data, says Black, and the community is just going to have to wait until the dust settles for a definitive answer.

Newsletter

Stay up to date on the most recent and practice-changing oncology data


Latest CME